Volume | 1,694,410 |
|
|||||
News | - | ||||||
Day High | 130.61 | Low High |
|||||
Day Low | 121.80 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sarepta Therapeutics Inc New | SRPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
123.00 | 121.80 | 130.61 | 127.39 | 124.25 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
25,888 | 1,694,410 | $ 127.38 | $ 215,831,760 | - | 55.25 - 159.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:51:07 | 1 | $ 124.26 | USD |
Sarepta Therapeutics (SRPT) Options Flow Summary
Sarepta Therapeutics Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
11.95B | 93.86M | - | 1.24B | -535.98M | -5.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sarepta Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 118.01 | 130.61 | 114.37 | 119.39 | 819,578 | 9.38 | 7.95% |
1 Month | 131.16 | 131.16 | 114.37 | 122.91 | 675,011 | -3.77 | -2.87% |
3 Months | 119.98 | 143.00 | 114.37 | 126.34 | 820,849 | 7.41 | 6.18% |
6 Months | 112.39 | 143.00 | 55.25 | 100.13 | 1,333,344 | 15.00 | 13.35% |
1 Year | 126.75 | 159.89 | 55.25 | 110.30 | 1,253,496 | 0.64 | 0.50% |
3 Years | 71.37 | 159.89 | 55.25 | 102.26 | 1,108,845 | 56.02 | 78.49% |
5 Years | 118.00 | 181.83 | 55.25 | 107.53 | 1,130,633 | 9.39 | 7.96% |
Sarepta Therapeutics Description
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. |